5.7 C
New York
Monday, January 30, 2023

Is DexCom Inc. (NASDAQ: DXCM) The Best Stock To Invest In?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for DexCom Inc. (DXCM) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.20, or 0.17%, to $118.23. The DexCom Inc. has recorded 92,217 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Stocks Info

DexCom Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Diagnostics & Research industry. At the end of the last regular session, the stock closed at $118.03 and fluctuated between $119.98 as its day high and $116.25 as its day low. The current market capitalization of DexCom Inc. is $44.82B. A total of 2.05 million shares were traded on the day, compared to an average of 2.82M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, DXCM has seen 2 BUY and 0 SELL insider trades, representing the acquisition of 35,500 and the disposition of 0 shares. Over the last 12 months, there were 41 BUYs and 111 SELLs from insiders. Insiders purchased 191,383 shares during that period but sold 101,432.

In the most recent transaction, Sylvain Jereme M sold 2,400 shares of DXCM for 112.62 per share on Nov 21. After the transaction, the EVP Chief Financial Officer now owns 67,237 company shares. In a previous transaction on Sep 01, Dolan Matthew Vincent sold 5 shares at 81.63 per share. DXCM shares that SVP Corporate Strategy-Develop owns now total 26,536.

Among the insiders who sold shares, Pacelli Steven Robert disposed of 1,000 shares on Aug 23 at a per-share price of $84.21. This resulted in the EVP Managing Director Dexcom V holding 137,700 shares of DXCM after the transaction. In another insider transaction, Pacelli Steven Robert sold 1,000 shares at $83.07 per share on Jul 25. Company shares held by the EVP Managing Director Dexcom V now total 138,700.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for DXCM in the last 3 months, the mean price target is $124.56 with high estimates of $140.00 and low estimates of $103.00. In terms of 52-week highs and lows, DXCM has a high of $144.96 and a low of $66.89.

As of this writing, DXCM has an earnings estimate of $0.3 per share for the current quarter. EPS was calculated based on a consensus of 17 estimates, with a high estimate of $0.34 per share and a lower estimate of $0.25. The company reported an EPS of $0.17 in the last quarter, which was -10.50% lower than expectations of $0.19.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 20 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DXCM is Sell with a score of 4.67. A total of 13 analysts rated the stock as Buy while 3 rated it as Overweight while 3 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles